To identify individuals at higher risk of developing AD or dementia, APOLIPOPROTEIN (APOE) and amyloid PET testing are being incorporated in clinical (drug) trials and prospective studies as screening tools (e.g., Alzheimer’s Prevention Initiative Generation Program [51]; Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study [52]; AMYPAD Diagnostic and Patient Management Study [53]). Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.